✦ LIBER ✦

Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Trial

✍ Scribed by Kim, Sang-Hyun; Kim, Min-Kyung; Seo, Hong-Seok; Hyun, Min-Soo; Han, Kyoo-Rok; Cho, Seong-Wook; Kim, Young-Kwon; Hoon Park, Seong

Book ID: 121769135
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 265 KB
Volume: 35
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2013.06.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, multicenter,

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

✍ Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki, Kusuki N 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 370 KB

Efficacy and Safety of Ezetimibe Coadmin

Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Capece, Rachel; Mitchel, Yale B.; Goldberg, Anne C.; Sapre, Aditi; Liu, Ji 📂 Article 📅 2004 🏛 Mayo Clinic 🌐 English ⚖ 125 KB

Efficacy and safety of golimumab in pati

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

✍ Robert D. Inman; John C. Davis Jr.; Désirée Van Der Heijde; Laura Diekman; Joach 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1

Efficacy and safety of adalimumab in pat

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

✍ Désirée van der Heijde; Alan Kivitz; Michael H. Schiff; Joachim Sieper; Ben A. C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Safety and efficacy of esreboxetine in p

Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial

✍ Lesley M. Arnold; Ian Hirsch; Paul Sanders; Amanda Ellis; Bernadette Hughes 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Efficacy and safety of four doses of lum

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m